← Back to headlines
New Alzheimer's drugs show more risks than benefits in study
New Alzheimer's drugs, including Lecanemab and Donanemab, which were initially met with high hopes, have disappointed in a recent study, showing more risks than benefits.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
